# Calida Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calida-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Total disclosed funding: $2.2M
- Latest round: Seed (Apr 6, 2023)
- Investors on record: 1

## About

Based in Paris, France, and founded in 2022, Calida Therapeutics operates as a preclinical stage biotechnology company specialising in thrombo-inflammatory disorders. The company was co-founded by Dr. Yunmei Wang and Dr. Daniel Simon. As of April 2023, the company is led by its CEO, Clement Bertholet. In April 2023, Calida Therapeutics raised EUR 2 million in seed funding, led by investor AdBio Partners. 

Calida is developing monoclonal antibodies that can be used to treat and prevent thrombo-inflammatory diseases that can arise in a variety of illnesses, ranging from cardiovascular disease to autoimmune disease complications. The company aims to break the molecular link between thrombosis and inflammation by limiting cross-talk between platelets and myeloid cells, preventing the chain reaction of these two events, which can cause tissue damage and life-threatening events. As of 2023, the company's product is still in preclinical testing and has yet to be commercialised.

The company plans to use the April 2023 funding to support preclinical trials and hire a lead partner.

## Funding rounds

- Seed, Apr 6, 2023, $2.2M — AdBio Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed